Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
- Conditions
- Large Cell Lymphoma
- Registration Number
- NCT00099255
- Lead Sponsor
- Seagen Inc.
- Brief Summary
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method To investigate the toxicity profile of SGN-30 To determine the objective response rate in patients with pcALCL, T-MF, and LyP To determine the duration of response in patients treated with SGN-30
- Secondary Outcome Measures
Name Time Method To provide preliminary estimates of disease-free and overall survival rates in pcALCL and T-MF patients treated with SGN-30 To determine the immunogenicity of SGN-30
Trial Locations
- Locations (13)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
University of California at Los Angeles
🇺🇸Los Angeles, California, United States
Stanford University
🇺🇸Stanford, California, United States
Yale
🇺🇸New Haven, Connecticut, United States
Northwestern Universtiy
🇺🇸Chicago, Illinois, United States
University of Illinois at Chicago
🇺🇸Chicago, Illinois, United States
Johns Hopkins
🇺🇸Baltimore, Maryland, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Memorial Sloan-Kettering
🇺🇸New York, New York, United States
Cleveland University
🇺🇸Cleveland, Ohio, United States
Scroll for more (3 remaining)University of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States